Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

pertussis

Vaccines Today

Vaccines Today—July 3, 2026

This week’s Vaccine and Immunotherapy update highlights regulatory progress,…

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for pertussis vax

Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for…

by Timos Papagatsias

Vaccines_News

Vaccines Video Recap—December 12, 2025

This biweekly Vaccines video recap highlights covers regulatory/policy…

Vaccines

Vaccines Today—December 5, 2025

This week’s vaccines update highlights key clinical findings, regulatory…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
LucidScope AI Audit Analyses
Public Health News
Monthly Strategic Roundups
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Women’s Health Strategic Roundup | June 24 – August 4, 2026
Curium Lantheus Merger | Lucid Diligence Brief
Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
Healthcare AI and Digital Health Strategic Roundup | July 3 – August 2, 2026
Roche Ivy Tech Laboratory Workforce Partnership | Lucid Diligence Brief

Tags

AAV Gene Therapy ACC 2025 ACLF ailux Attention Deficit Hyperactivity Disorder Azafaros Beclometasone/Formoterol Blinatumomab cholera commercial launches Corneal Endothelial Disease Coronavirus Disease 2019 Daewon Pharmaceutical Elecsys pTau181 epidermolysis bullosa Fanconi anemia geneventiv therapeutics Global Health Research graft-versus-host disease Healthcare AI Infrastructure IAS 2025 Imviva Biotech Infex Therapeutics Isomorphic Labs Lebrikizumab MajesTEC-9 Major depressive disorder Mirai Bio Motixafortide mursla bio Namodenoson Nanox.AI nvidia Oxaliplatin PCSK9 inhibitor ProFound Therapeutics progressive multiple sclerosis RA Capital RATIONALE-309 RNAi therapeutics roflumilast 0.05% strategic collaboration Surgical retina TCT Vanzacaftor/Tezacaftor/Deutivacaftor

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Women’s Health Strategic Roundup | June 24 – August 4, 2026
Curium Lantheus Merger | Lucid Diligence Brief
Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
Healthcare AI and Digital Health Strategic Roundup | July 3 – August 2, 2026
Roche Ivy Tech Laboratory Workforce Partnership | Lucid Diligence Brief

TAGS

AAV Gene Therapy ACC 2025 ACLF ailux Attention Deficit Hyperactivity Disorder Azafaros Beclometasone/Formoterol Blinatumomab cholera commercial launches Corneal Endothelial Disease Coronavirus Disease 2019 Daewon Pharmaceutical Elecsys pTau181 epidermolysis bullosa Fanconi anemia geneventiv therapeutics Global Health Research graft-versus-host disease Healthcare AI Infrastructure IAS 2025 Imviva Biotech Infex Therapeutics Isomorphic Labs Lebrikizumab MajesTEC-9 Major depressive disorder Mirai Bio Motixafortide mursla bio Namodenoson Nanox.AI nvidia Oxaliplatin PCSK9 inhibitor ProFound Therapeutics progressive multiple sclerosis RA Capital RATIONALE-309 RNAi therapeutics roflumilast 0.05% strategic collaboration Surgical retina TCT Vanzacaftor/Tezacaftor/Deutivacaftor

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy